Cure8 research brief
If true, a common gut microbe (Fusobacterium nucleatum) and its metabolite succinic acid could worsen intestinal inflammation by changing macrophage behavior, suggesting new targets to reduce flares or mucosal injury in IBD.
Researchers studying the gut microbiome and immune mechanisms in IBD, clinicians interested in emerging preclinical insights, and patients following microbiome-related research.
This study links Fusobacterium nucleatum to worse colitis through production of succinic acid, which the authors report raises SUCNR1 receptor expression on intestinal macrophages and activates NF-κB signaling to drive pro-inflammatory macrophage changes and epithelial injury.
The findings are based on human fecal and mucosal sampling, comparative metabolomics, multiple experimental colitis models, bacterial genetic knockouts (frdA-KO) that reduce succinic acid production, and complementary in vitro macrophage assays.
Blocking SUCNR1 (siRNA) or inhibiting NF-κB reduced succinic-acid–driven macrophage activation in the experiments described. The authors propose a Fusobacterium–succinic acid–SUCNR1–NF-κB axis as a potential therapeutic target in IBD, but the work reported is preclinical and focused on mechanistic biology rather than clinical testing.
This is mechanistic, preclinical research reported in an abstract/full-text PubMed entry; it does not provide evidence that targeting SUCNR1 or succinic acid is safe or effective in people with IBD yet.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies a specific protein interaction that may underlie persistent inflammation; for people with Crohn’s and other inflammatory conditions this points to a potential new, more targeted treatment approach in...
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies...
